BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15936507)

  • 1. The role of von Hippel-Lindau protein in the differentiation of neural progenitor cells under normoxic and anoxic conditions.
    Tanaka Y; Kanno H; Dezawa M; Mimura T; Kubo A; Yamamoto I
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):28-32. PubMed ID: 15936507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation.
    Kim WJ; Cho H; Lee SW; Kim YJ; Kim KW
    Int J Oncol; 2005 Apr; 26(4):1049-52. PubMed ID: 15754001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S; Desrosiers RR; Beliveau R
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity.
    Li Z; Wang D; Na X; Schoen SR; Messing EM; Wu G
    EMBO J; 2003 Apr; 22(8):1857-67. PubMed ID: 12682018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation.
    Kanno H; Saljooque F; Yamamoto I; Hattori S; Yao M; Shuin T; U HS
    Cancer Res; 2000 Jun; 60(11):2820-4. PubMed ID: 10850421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha.
    Bae MK; Jeong JW; Kim SH; Kim SY; Kang HJ; Kim DM; Bae SK; Yun I; Trentin GA; Rozakis-Adcock M; Kim KW
    Cancer Res; 2005 Apr; 65(7):2520-5. PubMed ID: 15805242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW; Ratcliffe PJ
    Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubular stability affects pVHL-mediated regulation of HIF-1alpha via the p38/MAPK pathway in hypoxic cardiomyocytes.
    Teng M; Jiang XP; Zhang Q; Zhang JP; Zhang DX; Liang GP; Huang YS
    PLoS One; 2012; 7(4):e35017. PubMed ID: 22506063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of hypoxia-induced transcription in normoxia.
    Hägg M; Wennström S
    Exp Cell Res; 2005 May; 306(1):180-91. PubMed ID: 15878343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylprednisolone inhibits the proliferation and affects the differentiation of rat spinal cord-derived neural progenitor cells cultured in low oxygen conditions by inhibiting HIF-1α and Hes1 in vitro.
    Wang W; Wang P; Li S; Yang J; Liang X; Tang Y; Li Y; Yang R; Wu Y; Shen H
    Int J Mol Med; 2014 Sep; 34(3):788-95. PubMed ID: 24992925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
    Sun X; Kanwar JR; Leung E; Vale M; Krissansen GW
    Gene Ther; 2003 Dec; 10(25):2081-9. PubMed ID: 14595381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha.
    Moon EJ; Jeong CH; Jeong JW; Kim KR; Yu DY; Murakami S; Kim CW; Kim KW
    FASEB J; 2004 Feb; 18(2):382-4. PubMed ID: 14688211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.